www.dashpct.com
FDA issued a warning letter to www.dashpct.com, a Malaysia-based website, for selling unapproved and misbranded semaglutide drug products — specifically 'Rybelsus 14mg' and 'Rybelsus 7mg' — to U.S. consumers over the internet without valid FDA-approved drug applications. The site falsely represented these products as FDA-approved while selling them without a prescription or licensed practitioner oversight, violating sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act. FDA demanded the site cease sales of unapproved and misbranded drugs and respond within 15 working days. Failure to comply may result in seizure and injunction.
Flagged claims (1)
Rybelsus is a brand‐name prescription medication that's FDA‐approved to treat type 2 diabetes. The drug helps control blood sugar in adults when used with diet and exercise.
Required actions (3)
FDA requests that www.dashpct.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers.
Please notify this office in writing within 15 working days describing the specific steps you have taken to address any violations and to prevent their recurrence.
Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction, without further notice.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most glp-1 / weight loss sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker